Currently available somatostatin analogs are not good for Graves' orbitopathy

Journal of Endocrinological Investigation

Volumn 29, Issue 5, 2006, Pages 389-390

  Tanda, M L ^a   Bartalena, L ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ANTIOXIDANT; CYTOKINE RECEPTOR ANTAGONIST; GLUCOCORTICOID; LONG ACTING DRUG; OCTREOTIDE; PLACEBO; RADIOACTIVE IODINE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5;

CLINICAL TRIAL; DECOMPRESSION SURGERY; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG RECEPTOR BINDING; EDITORIAL; ENDOCRINE OPHTHALMOPATHY; EYE SURGERY; HUMAN; PATIENT SATISFACTION; RECEPTOR AFFINITY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

EID: 33745889933     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03344119     Document Type: Editorial

References (18)

1. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000, 21: 168-99.
2. Ludgate M, Baker G. Inducing Graves' ophthalmopathy. J Endocrinol Invest 2004, 27: 211-5.
3. Bahn RS. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthalmopathy. J Endocrinol Invest 2004, 27: 216-20.
4. Marinò M, Chiovato L, Lisi S, Altea MA, Marcocci C, Pinchera A. Role of thyroglobulin in the pathogenesis of Graves' ophthalmopathy: the hypothesis of Kriss revisited. J Endocrinol Invest 2004, 27: 230-6.
5. Ajjan RA, Weetman AP. New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy. J Endocrinol Invest 2004, 27: 237-45.
6. Wiersinga WM, Prummel MF, Terwee CB. Effects of Graves' ophthalmopathy on quality of life. J Endocrinol Invest 2004, 27: 259-64.
7. Kahaly GJ, Petrak F, Hardt J, Egle UT. Psychosocial morbidity of Graves' orbitopathy. Clin Enclocrinol (Oxf) 2005, 63: 395-402.
8. Bartalena L, Tanda ML, Piantanida E, Lai A, Pinchera A. Relationship between management of hyperthyroidism and course of the ophthalmopathy. J Endocrinol Invest 2004, 27: 288-94.
9. Bartalena L, Wiersinga WM, Pinchera A. Graves' ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 2004, 27: 295-301.
10. Bartalena L, Marcocci C, Tanda ML, et al. An update on medical management of Graves' ophthalmopathy. J Endocrinol Invest 2005, 28: 469-78.
11. Pasquali D, Vassallo P, Esposito D, Bonavolontà G, Bellastella A, Sinisi AA. Somatostatin gene receptor expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. J Mol Endocrinol 2000, 25: 63-71.
12. Pasquali D, Notaro A, Bonavolontà G, Vassallo P, Bellastella A, Sinisi AA. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissue in Graves' disease. J Clin Endocrinol Metab 2002, 87: 5125-9.
13. Krassas GE. Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy. J Endocrinol Invest 2004, 27: 281-7.
14. Dickinson JA, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2004, 89: 5910-5.
15. Wemeau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with Graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 2005, 90: 841-8.
16. Chang T-C, Liao S-L. Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest 2006, 29: 413-22.
17. Bartalena L, Marcocci C, Pinchera A. Somatostatin analogs for Graves' ophthalmopathy: do they bounce off like a rubber bullet? J Clin Endocrinol Metab 2004, 89: 5908-9.
18. Boerlin V, van der Hoek J, Beglinger Ch, et al. New insights on SOM230, a universal somatostatin receptor ligand. J Endocrinol Invest 2003, 26 (Suppl): 14-6.